↓ Skip to main content

Dove Medical Press

Article Metrics

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol

Overview of attention for article published in Drug Design, Development and Therapy, May 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
35 Mendeley
Title
Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol
Published in
Drug Design, Development and Therapy, May 2015
DOI 10.2147/dddt.s80338
Pubmed ID
Authors

Xing-Huai Sun, Yuan Fang, Zhihong Ling

Abstract

Glaucoma is a common eye disease that can lead to irreversible vision loss if left untreated. The early diagnosis and treatment of primary open-angle glaucoma is challenging, and visual impairment in Chinese glaucoma patients is a serious concern. Most of these patients need more than one topical antiglaucoma agent to control their intraocular pressures (IOPs). In the People's Republic of China, the daily cost of different glaucoma medication varies greatly, and the treatment habits differ throughout the country. Prostaglandin analogs (PGAs) are recommended as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Fixed-combination drops, particularly PGA-based fixed combinations, have recently been developed and used in patients with progression or who have failed to achieve their target IOPs. Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combination (BTFC) in the People's Republic of China. BTFC has achieved good efficacy and tolerability in Chinese clinical trials. In addition, BTFC is more cost effective compared with other fixed combinations available in the People's Republic of China. Fixed-combination drops may offer benefits, such as keeping the ocular surface healthy, convenience of administration, and improvement in long-term adherence and quality of life. Therefore, BTFC has great potential for the treatment of Chinese glaucoma patients. However, the long-term efficacy of BTFC, comparisons of BTFC with other fixed-combination drugs, and treatment adherence and persistence with treatment in Chinese patients are unknown and will require further study.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 34 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 17%
Unspecified 5 14%
Other 4 11%
Student > Doctoral Student 3 9%
Student > Bachelor 3 9%
Other 7 20%
Unknown 7 20%
Readers by discipline Count As %
Medicine and Dentistry 18 51%
Unspecified 5 14%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Nursing and Health Professions 2 6%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 2 6%
Unknown 5 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2020.
All research outputs
#6,283,695
of 22,803,211 outputs
Outputs from Drug Design, Development and Therapy
#375
of 2,083 outputs
Outputs of similar age
#74,500
of 264,364 outputs
Outputs of similar age from Drug Design, Development and Therapy
#20
of 98 outputs
Altmetric has tracked 22,803,211 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.